Chief executive Andrew Witty denied accusations that the firm was profiteering from the demand for the swine flu drug.
He told the BBC that the firm had invested up to $2.5bn (£1.5bn) in the past three years to ensure that it could meet the government's demand for the drug.
And Mr Witty added that the firm was not charging more than it did for other seasonal flu drugs.
It was reported that the firm was charging the NHS £6 for each dose of Relenza, which cost it £1, but the company said this was "wrong".
Mr Witty would not be drawn on the costs of manufacturing the drug, but said typically the production cost was about 25% of the sale price.
"We are trying to strike a balance between society and our shareholders, who want to see a return on the risks we take.""(emphasis mine)
Is it me or this phrase sounds a little bit hypocrite?